

References

This is the reference list to the ACE Clinical Guideline “Lipid management: focus on cardiovascular risk”.

1. National Registry of Diseases Office. Singapore Myocardial Infarction Registry Annual Report 2020. Ministry of Health and Health Promotion Board, Singapore; 2022. Available from: https://nrdo.gov.sg/docs/librariesprovider3/default-document-library/smir-web-report-2020.pdf?sfvrsn=585f8334_1 [Accessed 8 November 2023]
2. National Registry of Diseases Office. Singapore Stroke Registry Annual Report 2020. Ministry of Health and Health Promotion Board, Singapore; 2022. Available from: https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/ssr-web-report-2020c544bb698cf04ad1aaaa7a1472296132.pdf?sfvrsn=33b4f18a_0 [Accessed 8 November 2023]
3. Posadzki P, Pieper D, Bajpai R, et al. Exercise/physical activity and health outcomes: an overview of Cochrane systematic reviews. *BMC public health*. 2020;20(1):1724.
4. Ding N, Sang Y, Chen J, et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. *Journal of the American College of Cardiology*. 2019;74(4):498–507.
5. 2020 Dietary Guidelines Advisory Committee, Dietary Patterns Subcommittee. Dietary Patterns and Risk of Cardiovascular Disease: A Systematic Review. Alexandria: VA: USDA Nutrition Evidence Systematic Review; 2020
6. Patnode CD, Evans CV, Senger CA, et al. Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. 2017;318(2):175-193.
7. 2018 Physical Activity Guidelines Advisory Committee. 2018 Physical Activity Guidelines Advisory Committee Scientific Report. Washington, DC: United States Department of Health and Human Services; 2018.
8. Palta P, Griswold M, Ranadive R, et al. Midlife Cardiovascular Health and Robust Versus Frail Late Life Status: The Atherosclerosis Risk in Communities Study. *J Gerontol A Biol Sci Med Sci*. 2022;77(6):1222-1229.
9. Dhamoon MS, Dong C, Elkind MS, et al. Ideal cardiovascular health predicts functional status independently of vascular events: the Northern Manhattan Study. *J Am Heart Assoc*. 2015;4(2):e001322.
10. World Health Organization. HEARTS Technical package for cardiovascular disease management in primary health care: healthy-lifestyle counselling. Geneva: World Health Organization; 2018.
11. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*. 2012;380(9841):581-590.
12. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376(9753):1670-1681.
13. Andelius L, Mortensen MB, Nørgaard BL, et al. Impact of statin therapy on coronary plaque burden and composition assessed by coronary computed tomographic angiography: a systematic review and meta-analysis. *Eur Heart J Cardiovasc Imaging*. 2018;19(8):850-858.
14. Yang W, Cai X, Lin C, et al. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2022;101(37):e30563.
15. Oh J, Lee CJ, Kim DI, et al. Target achievement with maximal statin-based lipid-lowering therapy in Korean patients with familial hypercholesterolemia: A study supported by the Korean Society of Lipid and Atherosclerosis. *Clinical cardiology*. 2017;40(12):1291–1296.
16. Perez de Isla L, Alonso R, Watts GF, et al. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. *J Am Coll Cardiol*. 2016;67(11):1278–1285.
17. Toth PP, Bray S, Villa G, et al. Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol. *J Am Heart Assoc*. 2022;11(18):e025551.

18. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139(25):e1082-e1143.
19. Leiter LA, Betteridge DJ, Farnier M, et al. Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. *Diabetes Obes Metab*. 2011;13(7):615-628.
20. Davidson M. Ezetimibe: a novel option for lowering cholesterol. *Expert Rev Cardiovasc Ther*. 2003;1(1):11-21.
21. Descamps O, Tomassini JE, Lin J, et al. Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients. 2015.
22. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. *N Engl J Med*. 2015;372(25):2387-2397.
23. Schmidt AF, Carter JL, Pearce LS, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2020;10(10):Cd011748.
24. Nissen SE, Dent-Acosta RE, Rosenson RS, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA*. 2016;315(15):1580-1590.
25. Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial. *J Clin Lipidol*. 2020;14(1): 88–97.e82.
26. Alder M, Bavishi A, Zumpf K, et al. A Meta-Analysis Assessing Additional LDL-C Reduction from Addition of a Bile Acid Sequestrant to Statin Therapy. *Am J Med*. 2020;133(11):1322-1327.
27. Giugliano RP, Wiviott SD, Blazing MA, et al. Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol: A Prespecified Analysis of the IMPROVE-IT Trial. *JAMA Cardiol*. 2017;2(5):547-555.
28. Lee M, Cheng CY, Wu YL, et al. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. *JAMA Neurol*. 2022;79(4):349-358.
29. Ziff OJ, Banerjee G, Ambler G, et al. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2019;90(1):75-83.
30. Cholesterol Treatment Trialists' Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet*. 2019;393(10170):407-415.
31. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet*. 2016;388(10046):761-775.
32. Mehta A, Virani SS, Ayers CR, et al. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. *Journal of the American College of Cardiology*. 2020;76(7):781–793.
33. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. *Circulation*. 2008;118(22):2243-2251.
34. Conrad N, Verbeke G, Molenberghs G, et al. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. *Lancet*. 2022;400(10354):733–743.
35. Patel RS, Pasea L, Soran H, et al. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. *Cardiovasc Diabetol*. 2022;21(1):102.
36. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. *J Am Coll Cardiol*. 2021;78(9):960-993.

37. Mottillo S, Filion KB, Genest J, et al. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. *J Am Coll Cardiol*. 2010;56(14):1113-1132.
38. Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, et al. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. *Cardiovasc Diabetol*. 2020;19(1):195.
39. Elder P, Sharma G, Gulati M, et al. Identification of female-specific risk enhancers throughout the lifespan of women to improve cardiovascular disease prevention. *American journal of preventive cardiology*. 2020;2:100028.
40. Peters SA, Woodward M. Women's reproductive factors and incident cardiovascular disease in the UK Biobank. *Heart*. 2018;104(13):1069-1075.
41. Goldfarb M, De Hert M, Detraux J, et al. Severe Mental Illness and Cardiovascular Disease: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2022;90(9):918-933.
42. Cunningham R, Poppe K, Peterson D, et al. Prediction of cardiovascular disease risk among people with severe mental illness: A cohort study. *PLoS One*. 2019;14(9):e0221521.
43. Sigvant B, Lundin F, Wahlberg E. The Risk of Disease Progression in Peripheral Arterial Disease is Higher than Expected: A Meta-Analysis of Mortality and Disease Progression in Peripheral Arterial Disease. *Eur J Vasc Endovasc Surg*. 2016;51(3):395-403.
44. Domanski MJ, Tian X, Wu CO, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. *Journal of the American College of Cardiology*. 2020;76(13):1507–1516.
45. Simha V. Management of hypertriglyceridemia. *BMJ*. 2020;371:m3109.
46. Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. *Cochrane Database Syst Rev*. 2015;2015(3):CD008226.
47. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. *Cochrane Database Syst Rev*. 2014;2014(11):CD010254.
48. Laufs U, Parhofer KG, Ginsberg HN, et al. Clinical review on triglycerides. *Eur Heart J*. 2020;41(1):99-109c.
49. Fruchart J. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. *Cardiovasc Diabetol*. 2017;16(1):124.
50. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. *J Am Coll Cardiol*. 2005;45(2):185-197.
51. Insani WN, Whittlesea C, Ju C, et al. Statin-related adverse drug reactions in UK primary care consultations: A retrospective cohort study to evaluate the risk of cardiovascular events and all-cause mortality. *Br J Clin Pharmacol*. 2022;88(11):4902-4914.
52. Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. *J Clin Lipidol*. 2016;10(4):739-747.
53. Cholesterol Treatment Trialists Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. *Lancet*. 2022;400(10355):832-845.
54. Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. *J Am Coll Cardiol*. 2021;78(12):1210-1222.
55. Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. *BMJ (Clinical research ed)*. 2021;372:n135.
56. Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2019;39(2):e38-e81.
57. Mancini GBJ, Baker S, Bergeron J, et al. Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update. *The Canadian journal of cardiology*. 2016;32(7 Suppl):S35–S65.
58. Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. *J Clin Lipidol*. 2023;17(1):19-39.

59. Strokes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015;36(17):1012-1022.
60. Kim EJ, Wierzbicki AS. Investigating raised creatine kinase. *BMJ*. 2021;373:n1486.
61. Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). *J Cachexia Sarcopenia Muscle*. 2022;13(3):1596-1622.
62. NHS Accelerated Access Collaborative. Statin intolerance pathway; 2020. Available from: <https://www.england.nhs.uk/aac/publication/statin-intolerance-pathway/> [Accessed March 2023]
63. LiverTox: Clinical and Research Information on Drug Induced Liver Injury. Atorvastatin. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK548236/> [Accessed 8 November 2023]
64. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy: Effect of Baseline Risk Factors for Diabetes. *J Am Coll Cardiol*. 2013;61(2):148–152.
65. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA*. 2011;305(24):2556-2564.
66. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. *Journal of clinical lipidology*. 2022;16(4):361–375.